ArticleThe oncologist2026
Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPatients with cutaneous squamous cell carcinoma (CSCC) and concurrent hematologic malignancy are underrepresented in clinical trials of anti-programmed death-1 (PD1) therapy due to concerns about efficacy and safety. The objective of this study is to evaluate clinical outcomes and safety of neoadjuvant anti-PD1 in patients with CSCC and concurrent hematologic malignancy.
methodsThis is a retrospective single-institution cohort study of neoadjuvant-intent anti-PD-1 therapy in patients with advanced CSCC and a concurrent hematologic malignancy. Patient and tumor characteristics are described. Clinical and pathologic response to anti-PD-1 therapy, safety, and CSCC recurrence risk and disease-specific survival are reported.
resultsTen patients with CSCC and a concurrent hematologic malignancy received immunotherapy with neoadjuvant intent. All patients were treated with cemiplimab, and 4/10 patients experienced a response by composite assessment of clinical, radiographic, and pathologic data. Two of eight patients who underwent planned surgical resection had a complete pathologic response, and 2 of 2 patients who did not undergo surgery had a clinical response on radiographic/clinical assessment. Three patients were receiving active treatment for hematologic malignancy during immunotherapy; of these, one demonstrated a clinical and pathologic response. One patient experienced a grade 3 immune-related adverse event (arthritis).
conclusionThe results suggest that anti-PD-1 therapy in the neoadjuvant setting in patients with CSCC and with concurrent hematologic malignancy is feasible. The clinical outcomes observed in this small cohort highlight the need for prospective studies of patients with concurrent hematologic malignancy in future neoadjuvant CSCC trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.